October 12, 2015 5:41pm

 

Get ready for your patience to be tested – I believe we have hit the final highs but, not the lowest lows! It hurts to be a naysayer but, someone has to provide a vestige of the truth! I am tired of the … ifs, tell me specifically … when!

Subscription required: http://www.regmedinvestors.com/user/register

 

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

U.S. stocks closed mildly higher Monday in low volume trading!

The NASDAQ closed UP +8.17 or +0.17% to 4,838.64 and the DOW closed UP +47.37 or +0.28% to 17,131.86.

 

 

Henry’omics:

  • The stem, cell, gene therapy and regenerative medicine (SCGT&RM) sector open reveling in the upside category but, by toward the end <11:30 am> of the am session was floundering to the downside!

Trade volume was one of the lightest for 2015 due to Columbus Day. The U.S. bond market was closed Monday for the holiday.

  • The NASDAQ closed above its 50-day moving average for the first time since 8/17. The Dow and S&P 500 closed above their 50-day moving averages last week and have remained above.

There are days even I am fed-up – cut the grass <picking up the acorns mostly – is that like the mess we’re in> and utilized the blower (6 hours) <saving myself filling 20 bags that would have gone to the dump to the lot next door – I was recycling and creating vegetation spots > - “BS”, I was trying to avoid the endless downturns on small volumes and fed-up with the lack of communication from sector “participants”!

  • And “our” universe “pooped the bed”; I believe we're seeing just a continuation of the same trends from last week!

Reiterating, the stem, cell and gene therapy RegMed sector has gone from drastically over-sold to over-bought and then back to parity – again and then again; in my estimation it’s time to get beyond the trading craze!

  • Up, down, round and round, the cell and gene therapy RegMed sector closed POSITIVE on Friday, Thursday and Wednesday, NEGATIVE on Tuesday following a POSITIVE close on last Monday. What’s a down day without a follow-on up day in a week?

Until after quarterly financial results <i.e. notice I didn’t say earnings> season kicks in, share pricing will continue to dance the limbo.

  • The SCGT&RM sector is running out of buyers but, not speculators or even the dark pools of algorithmic trading!
  • The NASDAQ Biotechnology index (NBI) closed UP +1.99 or +0.06% on Monday following Friday’s +18.06 or +0.56%;
  • The iShares Nasdaq Biotechnology ETF (IBB) eked out a gain of 0.03% after closing UP +1.25 or +0.41% on Friday;
  • The Russell 2000 (IWM) closed DOWN -0.17 or -0.15% on Monday following Friday’s advance of +0.23 or +0.20%;
  • The SPDR SD&P Biotech ETF (XBI) closed DOWN -0.79 or -1.22% following Friday’s advance of +1.11 or +1.74%;
  • The NYSE ARCA Biotech Index (BTK) closed DOWN On Monday -17.97 or –o.45% following Friday’s decline of -17.97 or -0.45%.      

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • SCGT & RM equities opened positive with an A/DL of 23/18 and 2 flats;
  • Until the morning flipped to the negative mid-day A/DL of 11/28 and 3 flats;
  • The closing bell stayed negative with an A/DL of 9/32 and 2 flats

My fear gauge of fear - the CBOE Volatility Index (VIX) traded above 15 <getting lower and not without hardship>from the morning’s below 17.

 

 

Dosing the sector – 43 Patients:

  • Open: POSITIVE with 18 decliners, 23 advancers and 2 flats;
  • Mid-day (1 pm) NEGATIVE with 28 decliners, 11 advancers and 3 flats;
  • Closing bell: NEGATIVE with 32 decliners, 9 advancers and 1 flat

 

 

Monday’s trading indications: 1 hit/ 6 miss:

  • Applied Genetic Technologies (AGTC) closed DOWN - $0.13 - Biogen’s BUY-IN of $20.62 is NOT even considered. - Still a miss;
  • blue bird bio (BLUE) closed DOWN -$1.66 – miss;
  • Capricor (CAPR) closed UP +$0.03 – miss, do not be fooled by short term volume and price appreciation – an offering is soon to be announced – still a miss;
  • Cellectis ADR (CLLS) closed DOWN – miss;
  • Juno Therapeutics (JUNO) closed UP – miss;
  • Spark Therapeutics (ONCE) closed DOWN – hit;

 

 

Who is UP – highest 5:

  • Juno Therapeutics (JUNO) closed UP +$2.04 to $50.68;
  • UniQure (QURE) +$0.56 to $20.12;
  • MiMedx (MDXG) +$0.44 to $9.84;
  • Fibrocell (FCSC) closed up +$0.35 to $4.53;
  • Intrexon (XON) +$0.24 to $36.25;

 

 

Who is down - the lowest 5:

  • Spark Therapeutics (ONCE) closed down -$2.05 to $47.25;
  • blue bird bio (BLUE)–-$1.66 to $87.14;
  • Kite Pharma (KITE) -$1.62 to $61.71;
  • Regenxbio (RGNX) -$1.25 to $19.28;
  • Cellectis ADR (CLLS) closed own -$0.53 to $26.08

 

 

Who is flat?

  • ReNeuron (RENE.L) at $3.875;
  • Mesoblast ADR (USOTC: MBLTY) at $12.08;

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.